1. |
Yuan D, Bao Y, El-Hashash A. Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic. Am J Stem Cells, 2024, 13(2): 37-58.
|
2. |
朱洁云, 高敏, 叶长广, 等. 慢性阻塞性肺疾病患者一年非计划再入院风险预测模型的构建. 中国呼吸与危重监护杂志, 2025, 24(1): 1-8.
|
3. |
曾黎静, 张嘉瑞, 易群. 慢性阻塞性肺疾病急性加重期合并II型呼吸衰竭列线图模型的构建及验证. 中国呼吸与危重监护杂志. 2024, 23 (12): 876-881.
|
4. |
Ma J, Li G, Wang H, et al. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties. Biomed Pharmacother, 2024, 173: 116282.
|
5. |
Bai X, Chen Q, Li F, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat Commun, 2024, 15(1): 6844.
|
6. |
Wang Y, Wang L, Ma S, et al. Repair and regeneration of the alveolar epithelium in lung injury. FASEB J. 2024, 38(8): e23612.
|
7. |
Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med, 2019, 13(9): 1738-1755.
|
8. |
Shaikh MS, Shahzad Z, Tash EA, et al. Human Umbilical Cord Mesenchymal Stem Cells: Current Literature and Role in Periodontal Regeneration. Cells, 2022, 11(7): 1168.
|
9. |
毛壮, 王华. 间充质干细胞治疗肺损伤研究进展. 军事医学, 2023, 4(9): 714-720.
|
10. |
赵培, 郭石平. 黑色素瘤缺乏因子2炎症小体在非感染性肺部疾病中的研究进展. 中国呼吸与危重监护杂志, 2025, 24(2): 147-152.
|
11. |
Saito A, Horie M, Micke P, et al. The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. Int J Mol Sci, 2018, 19(11): 3611.
|
12. |
Weis VG, Deal AC, Mekkey G, et al. Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol, 2021, 320(4): G658-G674.
|
13. |
Liu N, Cheng Y, Wang D, et al. Tissue-specific populations from amniotic fluid-derived mesenchymal stem cells manifest variant in vitro and in vivo properties. Hum Cell, 2024, 37(2): 408-419.
|
14. |
Fong CY, Chak LL, Subramanian A, et al. A three dimensional anchorage independent in vitro system for the prolonged growth of embryoid bodies to study cancer cell behaviour and anticancer agents. Stem Cell Rev Rep, 2009, 5(4): 410-9.
|
15. |
Ayuzawa R, Doi C, Rachakatla RS, et al. Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett, 2009, 280(1): 31-7.
|
16. |
Chen MY, Lie PC, Li ZL, et al. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol, 2009, 37(5): 629-40.
|
17. |
Mitchell KE, Weiss ML, Mitchell BM, et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells, 2003, 21(1): 50-60.
|
18. |
Malkowski A, Sobolewski K, Jaworski S, et al. FGF binding by extracellular matrix components of Wharton's jelly. Acta Biochim Pol, 2007, 54(2): 357-63.
|
19. |
Angelucci S, Marchisio M, Di Giuseppe F, et al. Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci, 2010, 26: 8: 18.
|
20. |
Friedman R, Betancur M, Boissel L, et al. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol. Biol Blood Marrow Transplant, 2007, 13(12): 1477-86.
|